Mprosevir
- Generic Name
- Mprosevir
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 1350
- Registration Number
- NCT06197217
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05752175
- Locations
- 🇨🇳
Shulan(Hangzhou) Hospital, Hangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath